 AUSTIN, Texas, July 22, 2021 PRNewswire -- Natera,Inc. NASDAQ: NTRA, a pioneer and global leader in cell-free DNA testing, today announced the publication of a new peer-reviewed study validating its personalized and tumor-informed molecular residual disease MRD assay, Signatera, for use in oligometastatic colorectal cancer oligo mCRC. Signatera has now been featured in 14 peer-reviewed publications. 